CA-NETAPP
28.8.2024 22:16:33 CEST | Business Wire | Press release
NetApp® (NASDAQ: NTAP), the original intelligent data infrastructure company, today announced new capabilities that support VMware Cloud Foundation deployments. Mutual customers will be able to leverage NetApp solutions to right-size their IT environments to run VMware workloads at scale efficiently.
For more than a decade, NetApp and VMware, recently acquired by Broadcom Inc., have collaborated to ensure the success of their joint customers and help them unlock the full value of their VMware investments. During that time, NetApp has been a key engineering design partner with VMware and is continuing to drive innovation in highly available, scalable and performant storage as a design partner for its Next-Generation vSphere Virtual Volumes (vVols). Now, NetApp is announcing new capabilities that will enable joint customers to run their VMware deployments more efficiently.
“NetApp and Broadcom are working together to take the uncertainty out of hybrid cloud environments,” said Jonsi Stefansson, Senior Vice President and Chief Technology Officer at NetApp. “More than 20,000 customers rely on NetApp to support their VMware workloads. NetApp's continued close collaboration with Broadcom following the acquisition of VMware ensures our solutions seamlessly interoperate so our mutual customers can leverage a single intelligent data infrastructure to operate their VMware workloads more efficiently.”
NetApp is helping optimize costs, simplify operations, and increase flexibility for customers running VMware environments by offering:
- Expanded Support for VMware Cloud Foundation (VCF): NetApp and Broadcom customers will now be able to simplify their VCF hybrid cloud environments by using NetApp ONTAP® software for all storage requirements, including standard and consolidated architectures. The latest release of ONTAP Tools for VMware (OTV) will support SnapMirror® active sync to provide symmetric active-active data replication capabilities for NetApp storage systems running VMware workloads. SnapMirror active sync allows customers to operate more efficiently by offloading data protection from their virtualized compute and improving data availability.
- New Capabilities for Azure VMware Solution (AVS): To support customers that are extending or migrating their vSphere workloads to the cloud, customers can now leverage Spot Eco by NetApp with AVS reserved instances to get the most value out of their deployments. Using Spot Eco to manage AVS reserved instances while also using Azure NetApp Files to offload data storage can reduce compute costs significantly.
- Enhanced VM Optimization Features for NetApp Cloud Insights: NetApp is introducing Cloud Insights VM Optimization, expanding its comprehensive solution for optimizing virtual environments, including VMware. Cloud Insights VM Optimization will give customers tools to reduce costs by increasing VM density, run storage at the best price-to-performance ratio for their environment, and monitor their entire environment to ensure availability, performance, and adherence to configuration best practices across the entire stack. To help customers optimize the compute, memory and storage resources of their VMware environments, NetApp is also offering customers a free 30-day trial of Cloud Insights to most cost-effectively migrate to the new VMware software subscriptions.
These offerings follow last month’s release of enhancements to NetApp BlueXP™ disaster recovery service, which provides guided workflows to design and execute automated disaster recovery plans for VMware workloads across hybrid cloud environments with newly added support for VMFS datastores.
“As organizations modernize infrastructure with VMware Cloud Foundation, they want to know that the services upon which they rely from industry-leaders such as NetApp will continue to work seamlessly and deliver the value they have come to expect,” said Paul Turner, Vice President of Products, VCF Division at Broadcom. “Having NetApp as a close collaborator helps our mutual customers deploy innovative data and storage services on top of their private cloud platform, and ensure they are getting the most value out of their VMware environments.”
“We have made Microsoft Azure the cloud of choice for VMware environments and offer fast and cost-effective solutions enabling many customers to move their VMware workloads to the cloud,” said Brett Tanzer, Vice President of Product Management at Microsoft. “As VMware customers navigate changes to operating virtualized environments, we have given our customers a way to lock in secure and predictable pricing over multiple years. NetApp's data management and cloud observability capabilities help our customers ensure those deployments are delivering the return on investment they need.”
“In an ever more complicated world of cloud, data, and infrastructure operations, IT teams are increasingly looking for holistic platforms over point solutions,” said Scott Sinclair, Practice Director, Enterprise Strategy Group. “These joint updates from NetApp and Broadcom enable customers to use NetApp’s intelligent data infrastructure to consolidate multiple data operations onto a single platform with industry-leading data management and CloudOps capabilities. That will help customers drive greater operational and infrastructure efficiencies that reduce the total cost of ownership for their VMware investments.”
Additional Resources
About NetApp
NetApp is the original intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828604243/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
